eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


4/2006
vol. 5
 
Share:
Share:
abstract:

Influence of six months’ transdermal 17β -oestradiol administration combined with oral medroxyprogesterone or oral simvastatin treatment on glycaemia and insulinaemia in postmenopausal women with normal and impaired glucose tolerance

Józef Krzysiek
,
Tomasz Milewicz
,
Krystyna Sztefko
,
Dorota Skucińska
,
Stanisław Radowicki

Prz Menopauz 2006; 4: 204–212
Online publish date: 2006/09/21
View full text Get citation
 

Aim of study: Comparison between influence of transdermal continuous 17β-oestradiol combined with oral medroxyprogesterone (HRT) and oral simvastatin treatment on glycaemia and insulinaemia in postmenopausal women with normal and impaired glucose tolerance.
Materials and methods: 68 postmenopausal women were allocated to six groups. Groups A, B and C consisted of women with normal glucose tolerance, while groups D, E and F had women with impaired glucose tolerance. Group A 17 patients, group D 11 patients. Both groups received HRT. Groups B (10 women) and E (10 women) received simvastatin 20 mg orally. Groups C (10 women) and F (10 women) were controls.
Results: Basic fasting FSH, oestradiol, DHEAS, SHBG insulin and plasma levels were assessed as well as glucose and insulin during OGTT. HRT increased plasma insulin levels in women with normal glucose tolerance and had no such effect in women with IGT. Simvastatin had no effect on plasma insulin and glucose levels in postmenopausal women with normal glucose tolerance and reduced fasting insulin level in women with IGT.
keywords:

17β-oestradiol, medroxyprogesterone, simvastatin, glucose, insulin, postmenopausal women

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.